Kite, a Gilead Company , and its partner Arcellx, today announced new positive data from its pivotal iMMagine-1 Phase 2 study of anitocabtagene autoleucel (anito-cel), an investigational agent, which ...
Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational ...
1don MSN
Home-based monitoring could transform care for patients receiving T-cell redirecting therapies
Patients who receive T-cell redirecting therapies are typically hospitalized for several days after treatment to watch for ...
Newly Appointed Members Include Leaders in Vaccine Immunology, T-Cell Science, and Clinical Research ATLANTA, GA - December ...
NeuMap, the first single‑cell atlas of neutrophils, reveals conserved functional hubs across health, infection, and cancer, reshaping immunity.
Two years after this, Sakaguchi was able to link these discoveries. He proved that the Foxp3 gene governs the development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback